Anacor nail fungus drug tavaborole under FDA review
This article was originally published in Scrip
Executive Summary
Shares of Anacor Pharmaceuticals rose as high as 6.8%, or 74 cents, on 2 October after the company revealed the US FDA had accepted for review the biotech's new drug application (NDA) for tavaborole, an experimental topical treatment for onychomycosis, a fungal infection of the nail and nail bed that affects about 35 million Americans.